Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
Amgen’s Acquisition of Horizon Therapeutics
AstraZeneca’s Acquisition of Neogene Therapeutics
Cooley advised Neogene Therapeutics on the deal. Neogene Therapeutics, a global clinical-stage biotechnology company, signed its definitive agreement to be acquired by AstraZeneca for a total consideration...
Roper Technologies’ Acquisition of Frontline Education
Cooley advised Frontline Education, while Davis Polk and Jones Day advised Roper Technologies on the deal. Kirkland & Ellis advised Thoma Bravo. Frontline Education, a leading...
Vertex’s $320 Million Acquisition of ViaCyte
Skadden advised Vertex Pharmaceuticals Incorporated on the deal while Cooley represented ViaCyte. Vertex Pharmaceuticals Incorporated (“Vertex”) has entered into a definitive agreement under which Vertex will acquire...
Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
Alvotech’s Merger with Oaktree Acquisition Corp. II
Cooley and Arendt advised Alvotech Holdings, while Kirkland & Ellis, working alongside Walkers and King & Spalding and Elvinger Hoss Prussen, advised Oaktree Acquisition Corp. II...